Log In Get Started
Press Releases July 29, 2026 08:30 AM

CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026

CorMedix Therapeutics schedules Q2 2026 financial results and corporate update for August 13, 2026

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
CRMD

CorMedix Therapeutics announced it will report its financial results for Q2 2026 on August 13, 2026, prior to market opening, followed by a corporate update conference call. The company focuses on developing and marketing therapeutic products for life-threatening conditions in institutional healthcare settings across the US.

CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026
CRMD
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Q2 2026 financial results to be reported on August 13, 2026 before market opens.
  • Corporate update conference call scheduled for the same day to provide business insights.
  • CorMedix focuses on therapeutic products for serious conditions, targeting institutional healthcare settings such as hospitals and clinics in the US.

PARSIPPANY, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026, and will host a corporate update conference call at 8:30am Eastern Time.

Thursday, August 13th @ 8:30am ETDomestic:1-844-676-2922International:1-412-634-6840Webcast:Webcast Link  

About CorMedix
CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases in the United States. CorMedix is focused on selling and marketing products in institutional settings of care in the US and has field based medical and commercial infrastructure deployed in hospitals, clinics and infusion centers. For more information visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
[email protected]
(617) 430-7576


Risks

  • Financial results may reveal challenges or underperformance affecting investor sentiment.
  • Dependence on institutional healthcare settings could limit market expansion amid healthcare facility constraints.
  • Biopharmaceutical sector risks include regulatory approvals, competition, and commercialization hurdles impacting revenue potential.

More from Press Releases

Axe Compute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Sep 11, 2026 EverCommerce Announces an Increase and Extension of its Share Repurchase Program Sep 11, 2026 Grupo Aeroportuario del Pacifico Announces the Execution of Bank Credit Facilities Totaling Ps. 8,000 Million Sep 11, 2026 Eastern International Ltd. Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency Sep 11, 2026 ArrowMark Financial Corp. Announces Q2 Results and Special Distribution of $0.10 and Monthly Cash Distribution of $0.15 per Share for September 2026 Sep 11, 2026